Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Adicet Bio ( (ACET) ).
On October 7, 2025, Adicet Bio announced promising preliminary results from its ADI-001 Phase 1 study for treating lupus nephritis (LN) and systemic lupus erythematosus (SLE). As of August 31, 2025, all seven patients showed significant improvements, with 100% achieving renal response and sustained reductions in disease activity scores. The treatment was well-tolerated, showing potential for outpatient administration, and demonstrated an immune reset effect. Adicet plans to engage with the FDA in early 2026 to design a Phase 2 pivotal trial, aiming to transform the treatment landscape for autoimmune diseases.
The most recent analyst rating on (ACET) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.
Spark’s Take on ACET Stock
According to Spark, TipRanks’ AI Analyst, ACET is a Underperform.
Adicet Bio faces significant financial challenges and technical weaknesses, with no revenue and ongoing losses as critical concerns. The poor valuation further impacts the stock’s appeal. While the new board appointment is positive, it does not mitigate the substantial risks present in the company’s financials and market performance.
To see Spark’s full report on ACET stock, click here.
More about Adicet Bio
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Average Trading Volume: 502,737
Technical Sentiment Signal: Hold
Current Market Cap: $83.25M
Learn more about ACET stock on TipRanks’ Stock Analysis page.